[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532907":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":193,"collaborators":25,"id":195,"slug":25,"hasResults":196,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":25,"eligibilityCriteria":200,"healthyVolunteers":196,"sex":201,"minAge":202,"maxAge":25,"enrollmentInfo":203,"targetDuration":25,"studyType":206,"phases":207,"briefSummary":209,"conditions":210,"keywords":217,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":237},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NT-112","EXPERIMENTAL","Part A Dose Escalation and Part B Dose Expansion of NT-112",[13],"Biological: NT-112: Autologous, engineered T Cells targeting KRAS G12D",{"label":15,"type":10,"description":16,"interventionNames":17},"AZD0240","Part A Dose Escalation and Part B Dose Expansion of AZD0240",[18],"Biological: AZD0240: Autologous, engineered T Cells targeting KRAS G12D",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","NT-112: Autologous, engineered T Cells targeting KRAS G12D","NT-112 targets KRAS G12D in the context of HLA-C\\*08:02",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"AZD0240: Autologous, engineered T Cells targeting KRAS G12D","AZD0240 targets KRAS G12D in the context of HLA-A\\*11:01 or HLA-A\\*11:02",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[37,50,58,66,75,84,93,102,111,119,124,133,142,150,159,168,176,184],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":25},"Research Site","RECRUITING","Duarte","California","91010","United States",{"type":45,"coordinates":46},"Point",[47,48],-117.97729,34.13945,{"lat":48,"lon":47},{"facility":38,"status":39,"city":51,"state":41,"zip":52,"country":43,"cosmosGeoPoint":53,"geoPoint":57,"contacts":25},"Los Angeles","90095",{"type":45,"coordinates":54},[55,56],-118.24368,34.05223,{"lat":56,"lon":55},{"facility":38,"status":39,"city":59,"state":41,"zip":60,"country":43,"cosmosGeoPoint":61,"geoPoint":65,"contacts":25},"Newport Beach","92663",{"type":45,"coordinates":62},[63,64],-117.92895,33.61891,{"lat":64,"lon":63},{"facility":38,"status":39,"city":67,"state":68,"zip":69,"country":43,"cosmosGeoPoint":70,"geoPoint":74,"contacts":25},"Jacksonville","Florida","32224",{"type":45,"coordinates":71},[72,73],-81.65565,30.33218,{"lat":73,"lon":72},{"facility":38,"status":39,"city":76,"state":77,"zip":78,"country":43,"cosmosGeoPoint":79,"geoPoint":83,"contacts":25},"Chicago","Illinois","60637",{"type":45,"coordinates":80},[81,82],-87.65005,41.85003,{"lat":82,"lon":81},{"facility":38,"status":39,"city":85,"state":86,"zip":87,"country":43,"cosmosGeoPoint":88,"geoPoint":92,"contacts":25},"Westwood","Kansas","66205",{"type":45,"coordinates":89},[90,91],-94.6169,39.04056,{"lat":91,"lon":90},{"facility":38,"status":39,"city":94,"state":95,"zip":96,"country":43,"cosmosGeoPoint":97,"geoPoint":101,"contacts":25},"Boston","Massachusetts","02115",{"type":45,"coordinates":98},[99,100],-71.05977,42.35843,{"lat":100,"lon":99},{"facility":38,"status":39,"city":103,"state":104,"zip":105,"country":43,"cosmosGeoPoint":106,"geoPoint":110,"contacts":25},"St Louis","Missouri","63110",{"type":45,"coordinates":107},[108,109],-90.19789,38.62727,{"lat":109,"lon":108},{"facility":38,"status":39,"city":112,"state":112,"zip":113,"country":43,"cosmosGeoPoint":114,"geoPoint":118,"contacts":25},"New York","10016",{"type":45,"coordinates":115},[116,117],-74.00597,40.71427,{"lat":117,"lon":116},{"facility":38,"status":39,"city":112,"state":112,"zip":120,"country":43,"cosmosGeoPoint":121,"geoPoint":123,"contacts":25},"10065",{"type":45,"coordinates":122},[116,117],{"lat":117,"lon":116},{"facility":38,"status":39,"city":125,"state":126,"zip":127,"country":43,"cosmosGeoPoint":128,"geoPoint":132,"contacts":25},"Portland","Oregon","97213",{"type":45,"coordinates":129},[130,131],-122.67621,45.52345,{"lat":131,"lon":130},{"facility":38,"status":39,"city":134,"state":135,"zip":136,"country":43,"cosmosGeoPoint":137,"geoPoint":141,"contacts":25},"Philadelphia","Pennsylvania","19107",{"type":45,"coordinates":138},[139,140],-75.16362,39.95238,{"lat":140,"lon":139},{"facility":38,"status":39,"city":143,"state":135,"zip":144,"country":43,"cosmosGeoPoint":145,"geoPoint":149,"contacts":25},"Pittsburgh","15237",{"type":45,"coordinates":146},[147,148],-79.99589,40.44062,{"lat":148,"lon":147},{"facility":38,"status":39,"city":151,"state":152,"zip":153,"country":43,"cosmosGeoPoint":154,"geoPoint":158,"contacts":25},"Nashville","Tennessee","37203",{"type":45,"coordinates":155},[156,157],-86.78444,36.16589,{"lat":157,"lon":156},{"facility":38,"status":39,"city":160,"state":161,"zip":162,"country":43,"cosmosGeoPoint":163,"geoPoint":167,"contacts":25},"Dallas","Texas","75246",{"type":45,"coordinates":164},[165,166],-96.80667,32.78306,{"lat":166,"lon":165},{"facility":38,"status":39,"city":169,"state":161,"zip":170,"country":43,"cosmosGeoPoint":171,"geoPoint":175,"contacts":25},"Galveston","77555",{"type":45,"coordinates":172},[173,174],-94.7977,29.30135,{"lat":174,"lon":173},{"facility":38,"status":39,"city":177,"state":161,"zip":178,"country":43,"cosmosGeoPoint":179,"geoPoint":183,"contacts":25},"Houston","77030",{"type":45,"coordinates":180},[181,182],-95.36327,29.76328,{"lat":182,"lon":181},{"facility":38,"status":39,"city":185,"state":186,"zip":187,"country":43,"cosmosGeoPoint":188,"geoPoint":192,"contacts":25},"Milwaukee","Wisconsin","53226",{"type":45,"coordinates":189},[190,191],-87.90647,43.0389,{"lat":191,"lon":190},{"type":194,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100532907",false,"NCT06218914","Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and\u002For Metastatic Solid Tumors","Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and\u002For Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosed with NSCLC, Colorectal adenocarcinoma, Pancreatic adenocarcinoma, Endometrial Cancer or any other solid tumor\n* Tumors must harbor a KRAS G12D variant mutation and subject must be HLA-C\\*08:02 positive, HLA-A\\*11:01 or HLA-A\\*11:02 positive in at least one allele\n* Subject has advanced solid cancer, defined as unresectable, advanced, and\u002For metastatic disease (Stage III or IV) after at least 1 line of approved systemic standard of care (SOC) treatment regimen and for which there are no available curative treatment options.\n* Presence of at least 1 measurable lesion per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at the time of enrollment\n\nKey Exclusion Criteria:\n\n* Any other primary malignancy within the 3 years prior to enrollment (except for non-melanoma skin cancer, carcinoma in situ (eg, cervix, bladder, breast) or low-grade prostate cancer\n* Known, active primary central nervous system (CNS) malignancy\n* History of prior adoptive cell and gene therapy, allogeneic stem cell transplant or solid organ transplantation.\n* History of stroke or transient ischemic attack within the 12 months prior to enrollment.\n* History of clinically significant cardiac disease within the 6 months prior to enrollment or heart failure at any time prior to enrollment.\n* Systemic therapy within at least 2 weeks or 3 half-lives, whichever is shorter, prior to enrollment.\n* Any form of primary immunodeficiency.\n* Active immune-mediated disease requiring systemic steroids or other immunosuppressive treatment (except if related to prior checkpoint inhibitor therapy)\n* Female of childbearing potential who is lactating or breast feeding at the time of enrollment\n* Prior treatment with pan-KRAS or KRAS G12D targeting agents unless presence of KRAS G12D mutation is confirmed after the completion of treatment with pan-KRAS or KRAS G12D targeting agents.","ALL","18 Years",{"count":204,"type":205},108,"ESTIMATED","INTERVENTIONAL",[208],"PHASE1","Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and\u002For Metastatic Solid Tumors.",[211,212,213,214,215,216],"Non-small Cell Lung Cancer","Colorectal Carcinoma","Pancreatic Ductal Adenocarcinoma","Endometrial Cancer","Solid Tumor, Adult","KRAS G12D",[218,219,216,220,221,222,223,224,213,225,226,227],"TCR-T cell therapy","KRAS","Autologous","PDAC","NSCLC","Colorectal Cancer","Solid tumors","HLA-C*08:02","HLA-A*11:01","HLA-A*11:02","2026-06-30",{"date":230,"type":231},"2026-07-01","ACTUAL",{"date":233,"type":231},"2024-03-22",{"date":235,"type":205},"2043-11-18",{"name":5,"class":6},18]